Phase 4
Completed N=30
Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Source: ClinicalTrials.gov NCT03054740 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The primary purpose of this study is to determine if by offering a vapocoolant (cold spray) to hospital outpatients prior to an intravenous catheter (IV) insertion will increase patient satisfaction of IV insertion as well as determine if pain of insertion is decreased.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scale Using Visual Analog Scale |
1.13; 1.60 | — |
| SECONDARY Satisfaction Scale Using 1-5 Likert Scale |
2; 5; 13; 10 | .390 |
| SECONDARY Using the Same Likert Scale Rate How Satisfied the Patient Remembers the Last Time They Had IV Catheter Inserted |
1; 0; 2; 1; 0; 1 | — |
| SECONDARY Using the Same Visual Analog Scale Rate Pain the Last Time the Patient Remembers Having an IV Inserted |
3.40; 2.87 | — |
| SECONDARY Would Patient Choose to Have Intervention Again if IV Catheter Insertion is Needed |
12; 8; 3; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Any outpatient ordered to undergo a Nuclear Medicine Stress Test and is required to have IV access for injection of Radiopharmaceuticals
Exclusion Criteria
- If it is the first time the patient has had an intravenous catheter inserted
- Any patient who is or may be pregnant
- Any patient who is breast-feeding
- Any patient who has taken a narcotic, sedative and/or anti-anxiety medication within 8 hours of intervention time.
- Any patient who has a known diagnosis of Raynaud's Syndrome or Carpal Tunnel Syndrome.
- Any patient who has an allergy or hypersensitivity to Ethyl Chloride.
- Any patient under the age of 18 and/or any patient over the age of 85
- Any patient who is illiterate
- Any patient who is non-English speaking
- Any patient with prior experience with a vapocoolant spray.
Data sourced from ClinicalTrials.gov (NCT03054740). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.